> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Mesoblast Rexlemestrocel-L Cuts Cardiac Deaths: Study
- URL: https://www.fdaweb.com/mesoblast-rexlemestrocel-l-cuts-cardiac-deaths-study/
- Published: 2020-12-15T12:00:00.000Z
- Updated: 2026-09-14T16:40:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148308

Mesoblast says the DREAM-HF Phase 3 trial of its allogenic cell therapy rexlemestrocel-L (Revascor) in 537 patients with advanced chronic heart failure demonstrated a 60% reduction in the incidence of heart attacks or strokes and 60% reduction in death from cardiac causes when treated at an earlier stage in the progressive disease process. A company [statement](http://investorsmedia.mesoblast.com/static-files/162dd76a-6deb-47e9-b950-3497dfce1fbc?ref=fdaweb.com) says that despite the significant reduction in the pre-specified endpoint of cardiac death, there was no reduction in non-fatal decompensated heart failure events, which was the trial’s primary endpoint.

“This suggests that rexlemestrocel-L reduces mortality by mechanisms that are distinct from those of existing drugs that reduce hospitalization rates but do not significantly impact cardiac mortality,” the statement says.